Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

Guardado en:
Detalles Bibliográficos
Autores principales: Jean Galtier, Camille Alric, Emilie Bérard, Thibaut Leguay, Suzanne Tavitian, Audrey Bidet, Eric Delabesse, Jean Baptiste Rieu, Jean-Philippe Vial, François Vergez, Nicolas Lechevalier, Isabelle Luquet, Emilie Klein, Anne-Charlotte de Grande, Audrey Sarry, Arnaud Pigneux, Christian Récher, Sarah Bertoli, Pierre-Yves Dumas
Formato: article
Lenguaje:EN
Publicado: Nature Publishing Group 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/f96185a801b446e9a88718b9b046da3a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/f96185a801b446e9a88718b9b046da3a

Ejemplares similares